Citius Pharmaceuticals Reports Q3 2025 Financial Results with $9.2 Million Net Loss

Citius Pharmaceuticals, Inc. reported its financial results for the third quarter and nine months ended June 30, 2025, revealing a net loss of $9.2 million for the quarter, a decrease from a loss of $10.6 million in the same period last year. For the nine-month period, the company recorded a net loss of $31.0 million, compared to a loss of $28.3 million in the prior year. The company has not generated any revenue during these periods, continuing its reliance on financing activities to support operations. As of June 30, 2025, Citius had cash and cash equivalents of $6.1 million, a significant increase from $3.3 million at the end of the previous fiscal year.

Operating expenses for the third quarter totaled $8.8 million, down from $10.6 million in the same quarter of 2024. This decline was primarily driven by reduced research and development costs, which fell to $1.6 million from $2.8 million year-over-year, reflecting the completion of the Phase 3 trial for its Mino-Lok product. General and administrative expenses also decreased slightly to $4.4 million from $4.8 million. The company attributed the overall reduction in expenses to its ongoing efforts to streamline operations as it prepares for the commercial launch of its LYMPHIR product, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.

Citius has made strategic advancements, including entering into distribution agreements with Cardinal Health and Cencora to facilitate the anticipated U.S. launch of LYMPHIR in the fourth quarter of 2025. The company is transitioning from a development-stage entity to a commercial organization, with preparations for the launch of LYMPHIR underway. Additionally, Citius Oncology, a majority-owned subsidiary, has been actively engaged in capital-raising initiatives to extend its cash runway and support its operational needs.

The company’s total assets increased to $127.7 million as of June 30, 2025, up from $116.7 million at the end of the previous fiscal year, primarily due to an increase in cash and inventory. However, total liabilities also rose to $60.1 million, compared to $42.5 million in the prior year, largely driven by increased accounts payable and accrued expenses. Citius reported a negative working capital of approximately $27.2 million, raising concerns about its ability to continue as a going concern beyond September 2025 without additional financing.

Looking ahead, Citius Pharmaceuticals is focused on securing additional funding to meet its operational and milestone payment obligations, particularly related to LYMPHIR. The company has retained Jefferies LLC as its financial advisor to explore strategic alternatives aimed at maximizing shareholder value. While the company expects to have sufficient funds to continue operations through September 2025, it acknowledges the need for substantial additional financing to support its ongoing development and commercialization efforts.